Nykode Therapeutics (VACBF) announced last night that it has received notification from Genentech, a member of the Roche (RHHBY), of its ...

The potential blockbuster drug was approved by the agency more than a month before its scheduled decision date. A potential blockbuster cancer drug developed by Genentech Inc. and parent company ...

Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its PDUFA date, the agency approved the firm’s first-line breast cancer treatment ...

CuraSen has raised at least $90.7 million. Glaub was treasurer at South San Francisco-based Genentech Inc. for five years until 1990 and CFO at Cell Genesys before spending 12 years at Plexxikon ...

*Based on data released by the Federal Election Commission on September 23, 2024 except for independent expenditure and communication cost, contributions to federal candidates, and contributions from ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

Genentech Inc. will be cutting 436 jobs at its South San Francisco headquarters. Sanofi, which is headquartered in Paris, will also be cutting 100 jobs at its South SF office, according to notices ...

Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...

Roche Group unit Genentech said that the Food and Drug Administration approved Itovebi for treating certain breast cancer. The approval is for Itovebi in combination with palbociclib and ...